Procalcitonin as a Predictive Marker of Incident Liver Disease
Open Access
- 12 May 2025
- journal article
- Published by Wiley in Liver International
- Vol. 45 (6) , e70132
Abstract
Background and Aims: Previous studies have shown that procalcitonin (PCT) concentration is elevated in patients with liver disease without evidence of bacterial infection. We aimed to investigate the association between elevated PCT and the future risk of liver disease.Method: PCT was measured in 3897 individuals without known liver disease in the Malmö Diet and Cancer Cardiovascular Cohort (MDC‐CC) and in 3854 individuals in the Malmö Preventive Project cohort (MPP). Cox proportional hazards regression models were used to analyse the risk of register‐verified incident liver disease by PCT levels. We performed our analyses in a pooled sample of both the MPP and MDC‐CC cohorts, as well as separate analyses for each cohort.Results: 70 subjects in MDC‐CC and 49 subjects in MPP were diagnosed with non‐viral liver disease during a median follow‐up of 27.1 and 14.8 years, respectively. In multivariate adjusted models in the pooled sample, individuals with high PCT (> 0.05 ng/mL) had a significantly increased risk of developing liver disease compared to subjects with PCT concentrations below the cutoff (hazard ratio (HR) 3.4, 95% confidence interval (CI) 2.07–5.63, p < 0.001). The HR per standard deviation increase of log‐transformed PCT was 1.56 (95% CI 1.32–1.85, p < 0.001) in multivariate adjusted models. Separate cohort‐specific sensitivity analyses, including additional adjustment for C‐reactive protein, showed similar effect estimates as the pooled analyses.Conclusions: Elevated concentration of PCT independently predicts non‐viral liver disease. These findings could have implications for risk assessment but also highlight the possibility of PCT as a direct cause of hepatocyte damage.Keywords
Funding Information
- Svenska Sällskapet för Medicinsk Forskning
- Vetenskapsrådet
- Åke Wiberg Stiftelse
- Crafoordska Stiftelsen
- Direktör Albert Påhlssons Stiftelse
- Hjärt-Lungfonden
- Svenska Läkaresällskapet
- Skånes universitetssjukhus
This publication has 38 references indexed in Scilit:
- TLR4 enhances TGF-β signaling and hepatic fibrosisNature Medicine, 2007
- Clinical significance of serum procalcitonin levels in patients with acute or chronic liver diseaseEuropean Journal of Gastroenterology & Hepatology, 2006
- Sensitive Immunoluminometric Assay for the Detection of ProcalcitoninClinical Chemistry, 2002
- Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA.2002
- The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal functionEuropean Journal of Anaesthesiology, 2001
- Bacterial translocation of enteric organisms in patients with cirrhosisJournal of Hepatology, 2001
- Long‐term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidityJournal of Internal Medicine, 2000
- High serum procalcitonin concentrations in patients with sepsis and infectionThe Lancet, 1993
- Design and feasibilityJournal of Internal Medicine, 1993
- Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture.1992